The first batch of Covovax, a COVID-19 vaccine developed by Novavax Inc, is being manufactured at the Pune facility of the Serum Institute of India, according to SII CEO Adar Poonawalla on Friday.
“We are very excited to see the first batch of Covovax (developed by Novavax) being manufactured this week at our Pune facility. The vaccine has the potential to protect our children and grandchildren under the age of 18. The trials are still going on. Congratulations to the Serum Institute India team “Poonawalla stated this in a tweet.
Excited to witness the first batch of Covovax (developed by @Novavax) being manufactured this week at our facility in Pune. The vaccine has great potential to protect our future generations below the age of 18. Trials are ongoing. Well done team @seruminstindia! pic.twitter.com/K4YzY6o73A
— Adar Poonawalla (@adarpoonawalla) June 25, 2021
In March of this year, he stated that clinical trials for the Covovax vaccine had begun in India, with the company hoping to launch it by September of this year.
Novavax Inc, an American vaccine company, announced a licence agreement with SII in August 2020 for the development and commercialization of NVX-CoV2373, its COVID-19 vaccine candidate, in low and middle-income countries and India.
The Serum Institute began distributing the Covishield vaccine in the country in January of this year. To manufacture the vaccine, it had formed a partnership with the University of Oxford and AstraZeneca.